Education
About Us
Working with TipRanks
Follow Us
Aligos Therapeutics, Inc. (ALGS)
:ALGS
ALGS Stock Chart & Stats
Day’s Range― - ―
52-Week Range$5.05 - $46.80
Previous CloseN/A
Volume178.18K
Average Volume (3M)173.44K
Market Cap
$36.38M
Enterprise Value$201.60M
Total Cash (Recent Filing)$37.00M
Total Debt (Recent Filing)$8.38M
Price to Earnings (P/E)―
Beta1.91
Next Earnings
May 13, 2025EPS Estimate
-2.8Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-20.92
Shares Outstanding5,314,311
10 Day Avg. Volume164,380
30 Day Avg. Volume173,437
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)18.20
Price to Cash Flow (P/CF)-0.90
P/FCF Ratio0.00
Enterprise Value/Market Cap5.54
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit51.10
Enterprise Value/Ebitda-2.31
Forecast
1Y Price Target
$70.00Price Target Upside1076.47% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
---
Bulls Say, Bears Say
Bulls Say
Clinical Trial MilestoneThe initiation of ALG-000184's randomized, double-blind, active-controlled Phase 2 study is regarded as Aligos' next major milestone.
Efficacy And SafetyALG-000184 showcased robust and sustained antiviral activity in both HBeAg-positive and HBeAg-negative patients with CHB, highlighting its potential as a first-line therapy for long-term viral suppression.
Regulatory ProgressALG-000184 now has a clear regulatory pathway as a potential chronic suppressive therapy for HBV supported by both the FDA and the Center for Drug Evaluation (CDE) in China.
Bears Say
Investment RisksRisks to the investment thesis include negative data readouts, failure to secure regulatory approval, and potential delays in development timelines.
Regulatory ChallengesManagement plans to complete prerequisite activities by mid-2025 for ALG-055009's advancement into a Phase 2b study, with ongoing discussions with potential partners for its funding.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ALGS FAQ
What was Aligos Therapeutics, Inc.’s price range in the past 12 months?
Aligos Therapeutics, Inc. lowest stock price was $5.04 and its highest was $46.80 in the past 12 months.
What is Aligos Therapeutics, Inc.’s market cap?
Aligos Therapeutics, Inc.’s market cap is $36.38M.
When is Aligos Therapeutics, Inc.’s upcoming earnings report date?
Aligos Therapeutics, Inc.’s upcoming earnings report date is May 13, 2025 which is in 36 days.
How were Aligos Therapeutics, Inc.’s earnings last quarter?
Aligos Therapeutics, Inc. released its earnings results on Mar 10, 2025. The company reported -$13.08 earnings per share for the quarter, missing the consensus estimate of -$2.497 by -$10.583.
Is Aligos Therapeutics, Inc. overvalued?
According to Wall Street analysts Aligos Therapeutics, Inc.’s price is currently Undervalued.
Does Aligos Therapeutics, Inc. pay dividends?
Aligos Therapeutics, Inc. does not currently pay dividends.
What is Aligos Therapeutics, Inc.’s EPS estimate?
Aligos Therapeutics, Inc.’s EPS estimate is -2.8.
How many shares outstanding does Aligos Therapeutics, Inc. have?
Aligos Therapeutics, Inc. has 5,314,311 shares outstanding.
What happened to Aligos Therapeutics, Inc.’s price movement after its last earnings report?
Aligos Therapeutics, Inc. reported an EPS of -$13.08 in its last earnings report, missing expectations of -$2.497. Following the earnings report the stock price went down -19.552%.
Which hedge fund is a major shareholder of Aligos Therapeutics, Inc.?
Currently, no hedge funds are holding shares in ALGS
---
Aligos Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$70.00 (1076.47% Upside)
$70.00 (1076.47% Upside)
Hedge Fund Trend
Decreased
By 92.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.5%
Last 30 Days ▼ 2.4%
Last 30 Days ▼ 2.4%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-75.52%
12-Months-Change
Fundamentals
Return on Equity
-415.84%
Trailing 12-Months
Asset Growth
-53.31%
Trailing 12-Months
Company Description
Aligos Therapeutics, Inc.
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a s-antigen transport-inhibiting oligonucleotide polymer that is in Phase Ib clinical trial for the treatment of chronic hepatitis B (CHB); and ALG-000184, a capsid assembly modulator, which is in Phase I clinical trials to treat CHB. The company also develops ALG-020572, an antisense oligonucleotide to prevent HBsAg translation and secretion; and ALG-055009, a small molecule THR-ß agonist that is in the Phase 1a/1b for the treatment of non-alcoholic steatohepatitis(NASH). In addition, it develops siRNA drug candidate, ALG-125755, as well as ALG-125097 and ALG-125819, demonstrated potent inhibition of HBsAg release from HBV-infected cells. It has entered into license and collaboration agreements with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; Emory University to provide hepatitis B virus capsid assembly modulator technology; research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors; and Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH. The company was incorporated in 2018 and is headquartered in South San Francisco, California.
---
ALGS Stock 12 Month Forecast
Average Price Target
$70.00
▲(1076.47% Upside)
Technical Analysis
Gilead Sciences
―
Achieve Life Sciences
―
Arbutus Biopharma
―
Vertex Pharmaceuticals
―
Enanta Pharmaceuticals
―
Best Analysts Covering ALGS
1 Year
1 Year Success Rate
0/14 ratings generated profit
1 Year Average Return
-53.07%
assigned a buy rating 5 months ago
Copying Yasmeen Rahimi's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -53.07% per trade.
---